Table 3.
HRQoL, HCRU, and cost outcomes in the prior MDD medication treatment failure subgroup across MDD severity levels
| Outcomes | Participants with prior MDD medication treatment failure | |||
|---|---|---|---|---|
| Minimal/mild MDD (n = 517) | Moderate MDD (n = 244) | Mod severe MDD (n = 187) | Severe MDD (n = 129) | |
| Mean HRQoL scoresa | ||||
| SF-36v2 Mental Component Summary | 42.3 | 32.9*** | 27.5*** | 21.8*** |
| SF-36v2 Physical Component Summary | 47.8 | 45.8** | 45.8* | 43.9*** |
| EQ-5D VAS | 67.6 | 58.3*** | 55.0*** | 45.3*** |
| SF-6D Health State Utility Score | 0.65 | 0.57*** | 0.54*** | 0.51*** |
| EQ-5D-5L Utility Score | 0.76 | 0.70*** | 0.63*** | 0.52*** |
| Mean number of HCRU visits in the last 6 months | ||||
| Health care provider | 8.50 | 9.28 | 9.79 | 10.27 |
| Emergency department | 0.27 | 0.31 | 0.28 | 0.38 |
| Hospitalizations | 0.10 | 0.15 | 0.10 | 0.22* |
| Mean annualized total costs | ||||
| Indirect | $3124 | $5146** | $5237** | $7557*** |
| Cost of absenteeism | $884 | $1638 | $1831 | $2812* |
| Cost of presenteeism | $2143 | $3347** | $3300* | $4459** |
| Direct | $9852 | $12,303 | $10,035 | $15,420* |
| Total (indirect + direct) | $13,930 | $17,973* | $15,858 | $24,487** |
EQ-5D-5L EuroQol Five-Dimension 5 Level, EQ-5D VAS EuroQol Five-Dimension Visual Analogue Scale, HCRU health care resource utilization, HRQoL health-related quality of life, MDD major depressive disorder, Mod Severe moderately severe, SF-36v2 Short Form-36v2 Health Survey, SF-6D Short Form 6-Dimension
*P < 0.05, **P < 0.01, ***P < 0.001 vs minimal/mild MDD prior medication treatment failure cohort
aHigher EQ-5D VAS and SF-36v2 scores are indicative of better health and less disease severity. SF-6D health state utility scores and EQ-5D-5L utility scores closer to 1.0 indicate better health